A Randomised, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Inhaled Doses of Imatinib Inhalation Solution (AER-901) in Adult Healthy Volunteers
Latest Information Update: 12 Oct 2023
At a glance
- Drugs Imatinib (Primary) ; Imatinib
- Indications Pulmonary arterial hypertension; Pulmonary hypertension
- Focus Adverse reactions
- Sponsors Aerami Therapeutics
Most Recent Events
- 05 Oct 2023 According to an Aerami Therapeutics media release, extended pharmacokinetic findings from the completed Phase 1 clinical trial of AER-901 in healthy volunteers (NCT04903730) to support dose and dosing regimen selection for the planned uniPHied Phase 2 platform trial in PH-ILD and PAH will be presented at the upcoming CHEST 2023 conference
- 13 Sep 2023 Results presented at the 33rd Annual Congress of the European Respiratory Society
- 12 Sep 2023 According to an Aerami Therapeutics media release, results from this trial were presented at the 2023 European Respiratory Society (ERS) International Congress.